---
schema_version: "secwatch.filing_event.v1"
accession: "0001730430-26-000014"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:50:48.693885+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kiniksa reports Q4/FY 2025 net income; ARCALYST revenue up 62% to $677.6M; guides 2026 $900-920M

## Summary
- ARCALYST net product revenue $202.1M Q4, $677.6M FY 2025 (+62% YoY); gross-to-net improved to 8.4%.
- Net income $14.2M Q4, $59.0M FY 2025 vs net loss of $8.9M/$43.2M in prior-year periods.
- Cash, cash equivalents & short-term investments $414.1M, no debt, up from $243.6M.
- 2026 ARCALYST revenue guidance $900-$920M; company expects positive annual cash flow from operations.
- KPL-387 Phase 2/3 recurrent pericarditis data expected 2H 2026; KPL-1161 Phase 1 planned by end of 2026.

## SEC filing metadata
- accession: 0001730430-26-000014
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000173043026000014/0001730430-26-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000173043026000014/knsa-20260224x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730430-26-000014
- JSON: https://secwatch.observer/filing/0001730430-26-000014.json
- Plain text: https://secwatch.observer/filing/0001730430-26-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.